Insufficiency of phosphatase and tensin homolog (PTEN) occurs in numerous tumor types and has been implicated as a resistance mechanism to receptor tyrosine kinase-targeted therapies in human cancer. In this study, we have performed a comprehensive molecular and immunohistochemical characterization of PTEN in 58 imatinib-naı¨ve and 54 imatinib-treated gastrointestinal stromal tumors (GISTs). The findings were correlated with clinicopathological data. At the genomic level, PTEN was affected mainly by mono-allelic loss, which was significantly less frequent in imatinib-naı¨ve vs imatinib-resistant tumors (9% vs 39%, Po0.001). Neither PTEN mutations nor PTEN promoter hyper-methylation were found. By immunohistochemistry, PTEN depletion was clearly related to GIST progression. Low PTEN protein expression was common (50%) and often paralleled with total immunonegativity in imatinib-resistant tumors. The abnormal PTEN protein expression correlated with PTEN loss at the genomic level (P ¼ 0.001). In addition, the effect of small interfering RNA (siRNA) PTEN knockdown on KIT signaling was examined in GIST-T1 and GIST430 cell lines, in the absence or presence of a dual PI3K/mTOR inhibitor NVP-BEZ235, alone or in combination with imatinib. In both cell lines, siRNA silencing of PTEN resulted in the substantial upregulation of PI3K-AKT and MAPK pathways. The MAPK hyperactivation was further potentiated by NVP-BEZ235 in the imatinib-sensitive GIST-T1 cells; yet, this effect was counteracted efficiently by combined treatment. In the imatinib-resistant GIST430 cells, neither NVP-BEZ235 alone or in combination with imatinib yielded sufficient inhibition of hyper-phosphorylated MAPK and downstream intermediate S6 protein. In conclusion, depleted PTEN expression associated with mono-allelic PTEN loss occurs frequently in imatinib-resistant GIST and might serve as a biomarker for stratifying patients for optimal treatment. In vitro, the PTEN insufficiency leads to hyperactivation of AKT and MAPK pathways in tumor cells. Novel therapies targeting multiple components of the integrated KIT receptor signaling pathways in imatinibresistant GIST warrant further studies.
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Keywords: gastrointestinal stromal tumor; imatinib mesylate; PTEN; resistance The phosphatase and tensin homolog (PTEN) is a phosphatase able to convert membrane-associated phosphatidylinositol 3,4,5-triphosphate back to phosphatidylinositol 4,5-bisphosphate; thereby it negatively regulates the signaling transduction of the PI3K/AKT pathway. 1 After TP53, PTEN represents the second most frequently mutated tumorsuppressor gene in cancer. PTEN inactivation has a role in several human neoplasms, including glioblastoma, endometrial, prostate, colon, and breast carcinoma. In some of these tumors it has been demonstrated that PTEN deficiency is associated with advanced tumor stage and therapeutic resistance, especially to targeted therapies of receptor tyrosine kinases and their pathways. 2 In breast cancer, PTEN loss confers resistance to the anti-HER2 antibody trastuzumab. 3 Similarly, it promotes resistance to EGFR tyrosine kinase inhibitors in glioblastoma, colon, and lung cancer. [4] [5] [6] In gastrointestinal stromal tumors (GISTs), KIT and PDGFRA are fundamental therapeutic targets; however, the majority of GIST patients eventually develop resistance to imatinib mesylate and to other receptor tyrosine kinase inhibitors currently applied in the clinic. 7 This resistance is mainly due to the re-activation of KIT signaling by the acquisition of secondary KIT mutations. The PI3K/AKT/mTOR signaling pathway represents a crucial driving force for the growth, survival, and progression of GIST. 8 In human malignancies, PTEN inactivation or insufficiency constitutively activates this pathway. 9 Thereby, GIST patients with PTEN deficiency could benefit from alternative therapies targeting the PI3K/AKT/mTOR pathway. In line with this concept, an oral mTOR inhibitor everolimus (RAD001, Novartis Pharmaceuticals) has been tested in combination with imatinib in phase I-II clinical trials for patients with imatinib-resistant GIST, pointing to a potential therapeutic benefit of the combined administration. 10 Recent preclinical in vivo studies performed on GIST xenografts, using PI3K inhibitors in combination with imatinib, indicated synergistic and long-lasting effects, and suggested that PTEN inactivation could have an impact on the response to this therapy. 11, 12 Yet, currently no studies have been performed to investigate the range of PTEN abnormities in imatinib-resistant GIST patients.
In this study, we have performed a comprehensive molecular and immuno-histochemical characterization of PTEN in a heterogeneous cohort of GIST, to assess the incidence and the nature of PTEN malfunction during GIST progression and during the course of imatinib therapy. Furthermore, we have investigated the impact of small interfering RNA (siRNA) PTEN knockdown on KIT signaling in imatinib-sensitive and imatinib-resistant GIST cell lines treated with a dual PI3K/mTOR inhibitor alone or in combination with imatinib, in order to better understand the functional consequences of PTEN insufficiency in GIST cells.
Materials and methods
Pathologic GIST specimens, from patients who underwent a biopsy or surgical resection of their tumor at the University Hospitals of Leuven, Belgium, and at the Department of Soft Tissue/ Bone Sarcoma and Melanoma M. Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland, were retrieved from the Departments of Pathology of both institutions. Patients with advanced GIST were treated with imatinib in a dose 400-800 mg per day. The majority of these patients acquired resistance to imatinib, which was clinically defined as progressive tumor growth that occurred after an initial period 46 months on imatinib during which the patient had responsive disease. Both response and progression have been objectively assessed according to RECIST criteria. Clinical information was obtained from the databases and from review of medical charts. The local institutional ethics board of both participating institutions approved the study.
In total, 112 specimens from imatinib-naïve (n ¼ 58, 49 primary and 7 metastatic) and imatinibtreated (n ¼ 54; 48 imatinib-progressive and 6 imatinib-responsive) GIST were available for the analysis ( Table 1) .
The pathologic material was examined and the diagnosis of GIST was confirmed using hematoxylin and eosin staining and CD117 (KIT) immunohistochemistry on formalin-fixed, paraffin-embedded tissues, according to standard procedures. KIT/ PDGFRA genotyping was done as reported. 13 
PTEN Copy Number Loss, Mutational Analysis, and Methylation Status
Dual-color interphase fluorescence in situ hybridization (FISH) was performed on 85 paraffinembedded specimens, using LSI PTEN(10q23)/ CEP10 Probe (Abbott Laboratories, Green Oaks, IL, USA), as described. 12 The array comparative genomic hybridization (aCGH) data from 54 GIST included in this study were published before by our group. 14, 15 Mutational analysis of the entire coding sequence of PTEN (ENST00000371953-exons 1-9) was performed as described. 12 The primer sequences are listed in Table 2 .
The methylation status of the PTEN promoter (CpG Island 101755) was evaluated using the EpiTect Methyl qPCR Assay (Qiagen) according to the manufacturer's protocol. Universal Methylated Human DNA Standard (Zymo Research, Freiburg, Germany) and Human Genomic DNA (Roche, Basel, Switzerland) were used as positive and negative controls, respectively.
PTEN Expression Analysis
For the reverse-transcriptase quantitative PCR (RT-qPCR), total RNA (1 mg) was reverse transcribed with SuperScript III (Life Technologies, Carlsbad, CA, USA). The cDNA product was amplified using qPCR MasterMixPlus for SYBR s Green I without UNG (Eurogentec, Seraing, Belgium) in a Light Cycler 480 (Roche). The endogenous reference GADPH gene and the normal stomach tissues were used as references to normalize the results. PTEN The PTEN protein expression was assessed by immunohistochemistry in 112 GIST using anti-PTEN antibody (DAKO, Glostrup, Denmark; dilution 1:1000) previously validated on GIST xenografts with a known PTEN status. 12 Scoring for PTEN staining was semi-quantitative, based on the proportion and intensity of positive neoplastic cells (Figure 1) . It was performed in parallel by two observers using a four-tier system, ranging from 3 þ (450% immune-reactive cells and strong intensity equal to that of the vascular endothelium; Figures 1a and b), 2 þ (450% immune-reactive cells and weak intensity of staining; Figures 1c and d) , 1 þ (o50% immune-reactive cells, referred to as reduced staining; Figure 1e ) to 0 (completely negative; Figure 1f) . The categories 0 and 1 þ were considered to be abnormal.
In vitro siRNA PTEN Experiments
In vitro studies were performed on imatinibsensitive GIST-T1 (carrier of KIT-V560_Y579del mutation) and imatinib-resistant GIST430 (carrier of primary KIT-V560_L576del and secondary KIT-V654A mutations) cell lines.
The compounds, imatinib mesylate and the dual PI3K/mTOR inhibitor NVP-BEZ235, 16 were purchased from Sequoia Research Products (Pangbourne, UK).
The siRNA experiments were performed by the use of predesigned stealth RNAi duplexes against human PTEN (PTEN Validated Stealth RNAi:
PTENHSS183790 þ PTENHSS183791 þ PTENHSS183792; Invitrogen). Transient transfection was done in six-well plates at a density of 10 6 cells/plate with use of metafectene transfection reagent (Biontex, Planegg, Germany), according to the manufacturer's instructions. After 96 h, medium was exchanged for the one supplemented with dimethyl sulfoxide (Sigma-Aldrich, St Louis, MO, USA) only, or 100 nM NVP-BEZ235, or 200 nM imatinib, or the combination of both drugs in a given concentration. After 2 h of treatment, the cell pellets were collected for protein analysis by western blotting. The antibodies against total KIT and total PTEN (DAKO), total MAPK (Invitrogen), phospho-KIT, phospho-AKT, total AKT, phospho-MAPK, phospho-S6, total S6 (Cell Signaling, Beverly, MA), and B-actin (Sigma-Aldrich) were applied.
Statistics
For statistical analysis of the qPCR data, the Mann-Whitney U-test was applied. For analyses of the frequency of the genomic PTEN losses and the abnormal PTEN expression by immunohistochemistry, the w 2 or Fisher exact tests were applied. Differences with P-value o0.05 were defined as statistically significant. The software STATISTICA (Stat Soft, USA-version 9.0) was used for statistical calculations.
Results

PTEN Mono-Allelic Loss Occurs in the Progressive Stage of Disease and is Frequent in Imatinib-Treated Tumors
To assess the incidence of PTEN loss at the genomic level, we performed FISH analysis of 85 samples, and complemented these data with aCGH results available from 54 cases ( Within the imatinib-naïve group, PTEN loss was observed less frequently in very low/low/intermediate risk vs high risk/metastatic GIST (P ¼ 0.03; Table 3 ). Of note, the incidence of PTEN loss in imatinib-treated tumors was high (39%). As we did not have baseline pre-treatment tumor specimens available for comparison, we could not discriminate whether PTEN loss added to acquired resistance to imatinib or it was only a reflection of a more advanced stage of disease. Nevertheless, there was no correlation between the incidence of PTEN loss and the presence of secondary imatinib-resistant KIT mutations in GIST refractory to imatinib (P ¼ 0.6). Moreover, no significant differences were found between primary high risk/metastatic and imatinib-treated GIST (P ¼ 0.11). These results argue against the hypothesis that PTEN loss would be a direct cause of resistance to imatinib.
To further elucidate possible mechanisms responsible for aberrant PTEN expression, we performed mutational analysis of PTEN in 36 specimens (including 19 imatinib-progressive GIST). No somatic mutations were detected. In addition, we assessed PTEN promoter methylation in a total of 57 samples (including 24 imatinib-resistant GIST that lacked or expressed low level of PTEN protein by immunohistochemistry). None of the examined tumors exhibited methylation of PTEN promoter.
PTEN Mono-Allelic Loss Correlates with Altered PTEN Expression on Transcript and Protein Levels
By RT-qPCR, we investigated the expression of PTEN transcripts in 67 GIST (including 36 imatinib-resistant tumors). Abnormal PTEN expression was detected in 21% of samples. The low level of PTEN transcript expression correlated well with PTEN loss on the genomic level (P ¼ 0.002).
By immunohistochemistry, absent or reduced expression of PTEN protein was observed in 32% (n ¼ 36) of the tumors (Table 3 ). In the imatinibnaïve cohort, abnormal PTEN protein level was detected in high-risk/metastatic but not in low/ intermediate-risk tumors (45% vs 0%; Po0.001). In imatinib-treated tumors, abnormal PTEN expression was common (50%); notably, all 10 completely PTEN-immuno-negative GIST were from imatinibprogressive cohort. The abnormal PTEN protein expression correlated with PTEN loss at the genomic level (P ¼ 0.001).
siRNA-Induced Downregulation of PTEN Expression in GIST Cell Lines Results in PI3K-AKT-mTOR and MAPK Pathway Activations
In the PTENsi GIST-T1 and GIST430 cells, the level of PTEN protein was decreased by B50% and 80%, respectively, compared with non-PTENsi cells (Figure 2) .
In IM-S GIST-T1, PTEN silencing resulted in overactivation of AKT and MAPK (by 1.6-and 1.8-fold, respectively). The AKT hyper-phosphorylation was partially reverted by 100 nM NVP-BEZ235 in both PTENsi and non-PTENsi cells (by 70% and 85%, respectively). As expected, exposure to 200 nM imatinib led to complete AKT inactivation in non-PTENsi cells, opposite to PTENsi cells, in Interestingly, NVP-BEZ235 treatment gave rise to MAPK phosphorylation in non-PTENsi cells and at higher extent in PTENsi cells (2-and 2.8-fold, respectively). The MAPK activation was substantially and equally abolished by imatinib alone or 
Discussion
First, we carried out FISH and/or aCGH analysis of PTEN in a heterogeneous cohort of GIST. Monoallelic PTEN loss occurred in 24% of cases, whereas bi-allelic PTEN loss was encountered only in one tumor. In the imatinib-naïve GIST, a positive correlation between mono-allelic loss of PTEN and high-risk/metastatic tumors were found (P ¼ 0.03). These findings are in agreement with aCGH analysis reported by Ylipää et al, 17 as they observed the loss of chromosome 10q (on which PTEN maps) in the specific GIST subgroup, in patients with poor clinical outcome. As such, this event is likely to occur in the late stage of GIST evolution. As revealed by RT-qPCR analysis, PTEN loss was associated with substantially lower or absent PTEN transcript levels (P ¼ 0.002). In contrast to Yang et al., 18 we do not have evidence that receptor tyrosine kinase inhibitor treatment can cause loss of PTEN expression by epigenetic silencing, as we did not identify PTEN promoter methylation in any of the analyzed imatinib-resistant GIST. This finding together with the lack of evidence for inactivation of the PTEN by inactivating mutations suggests that the aberrantly low PTEN expression in GIST might be mainly due to mono-allelic loss.
Our findings were corroborated at the protein level by immunohistochemical analysis. In the imatinib-naïve cohort, reduced PTEN expression was mainly associated with the high-risk/metastatic tumors (Po0.001). An inverse correlation between PTEN immunoreactivity and disease progression in primary GIST has been previously reported. 19, 20 In our imatinib-treated GIST, the frequency of tumors with reduced or absent PTEN expression reached 50%. This result is notable because to the best of our knowledge data about the incidence of PTEN deficiency in imatinib-treated GIST has not been reported as of yet. Importantly, a subset of imatinib-progressive GIST with mono-allelic PTEN loss showed complete lack of PTEN reactivity by The effect of PTEN silencing on KIT downstream signaling was evaluated by western blotting under DMSO, imatinib, or NVP-BEZ235 alone, or combined treatment. For densitometry analysis, bands were normalized to actin expression and compared with control (diluting medium) as previously described. 12 immunohistochemistry, suggesting a bi-allelic inactivation. In these cases, we cannot exclude the presence of microdeletions/rearrangements of the second PTEN allele that were under the detection limit of the techniques used in the current study. Alternatively, other inactivation mechanisms might have a role, as PTEN expression could be positively and negatively regulated by transcription factors or microRNAs, as well as posttranslationally regulated by phosphorylation, oxidation, and acetylation. 1,2 Downregulation of PTEN results in hyperactivation of the PI3K/AKT/ mTOR pathway, leading to proliferative advantage of neoplastic cells. A similar role was attributed to PTEN in other types of cancers. 9 Subsequently, we explored the effect of siRNA PTEN silencing on KIT downstream signaling in vitro using GIST cell lines. Noteworthy, in both imatinib-sensitive and imatinib-resistant GIST cells, PTEN silencing resulted in overactivation of both, AKT and MAPK; the latter being exceptionally hyper-phosphorylated in imatinib-resistant cells. Overactivation of AKT was expected, as PTEN is a negative regulator of the PI3K-AKT pathway, whereas the latter might be explained by the extensive mTOR-negative feedback loops and cross-talks between the PI3K and the RAS-mediated MAPK pathways that have been well documented among the signaling networks driving tumor progression. 21, 22 Finally, we have investigated the effect of PI3K/ mTOR inhibition, alone or in combination with imatinib, on PTENsi GIST cell lines.
In imatinib-sensitive GIST-T1, NVP-BEZ235 treatment resulted in only partial inactivation of AKT in PTENsi cells, whereas enhancing the activation of MAPK. Nevertheless, the effect of PTEN silencing on AKT and MAPK activation in these cells was counteracted by imatinib alone and even more substantially by the combined treatment of NVP-BEZ235 and imatinib.
In imatinib-resistant GIST-430 cells, NVP-BEZ235 treatment led to less efficient AKT and MAPK inhibition in PTENsi in comparison to non-PTENsi cells. Likewise, imatinib did not inhibit sufficiently the overactivated MAPK and downstream S6 proteins in PTENsi cells. Combined treatment resulted in still substantial MAPK hyper-phosphorylation, and only partially counteracted S6 activation.
In summary, our data strongly support an important role for PTEN downregulation in GIST progression. Partial or total PTEN depletion occurs frequently in imatinib-resistant GIST. In vitro studies suggest that PTEN insufficiency leads to upregulation of the PI3K/AKT and MAPK pathways. Depending on the molecular context of the individual tumors, the MAPK activity might be even paradoxically further enhanced under certain dualspecific PI3K/mTOR inhibitors. Our results highlight the importance of molecularly sub-classifying GIST before exposing patients to innovative targeted treatments.
